30 Participants Needed

Personalized Cancer Vaccine for Multiple Myeloma

EE
AV
Overseen ByAmishi Vora
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but it does not allow treatment with corticosteroids (except for low doses) or prior chemotherapy for smoldering multiple myeloma. Bisphosphonates are allowed.

What data supports the effectiveness of the treatment Vaccine Therapy for Multiple Myeloma?

Research shows that cancer vaccines, including those using dendritic cells (special immune cells), can trigger strong immune responses against multiple myeloma, potentially leading to long-term disease control. Additionally, combining vaccines with other treatments like lenalidomide has shown promise in maintaining remission in patients.12345

Is the personalized cancer vaccine for multiple myeloma safe for humans?

Research on cancer vaccines for multiple myeloma, including those using dendritic cells and other immune strategies, is ongoing. While specific safety data for personalized cancer vaccines is limited, studies have explored similar vaccine approaches in multiple myeloma, suggesting they are generally safe, but more research is needed to confirm this.12467

How is the personalized cancer vaccine treatment for multiple myeloma different from other treatments?

The personalized cancer vaccine for multiple myeloma is unique because it aims to generate a specific immune response against the cancer by using the patient's own immune cells, potentially leading to long-term immunity and fewer side effects compared to traditional chemotherapy. This approach involves using dendritic cells, which are powerful immune cells, to present myeloma-specific antigens and stimulate a targeted attack on the cancer cells.12358

What is the purpose of this trial?

This early phase I trial studies the side effects of personalized vaccine in treating patients with smoldering multiple myeloma. Vaccines made from a person's blood and bone marrow may help the body build an effective immune response to kill cancer cells.

Research Team

Krina K. Patel | MD Anderson Cancer Center

Krina Patel

Principal Investigator

M.D. Anderson Cancer Center

Eligibility Criteria

This trial is for adults with smoldering multiple myeloma at intermediate or high risk of progression. Participants must have certain levels of plasma cells, kidney function, and blood counts, and be able to consent. Excluded are those with active myeloma, prior SMM treatment, other cancers, infections like TB or hepatitis B/C, pregnant women, and people with HIV.

Inclusion Criteria

My condition is confirmed as smoldering multiple myeloma without any signs of further complications.
I am at intermediate or high risk of my condition worsening to multiple myeloma according to specific health criteria.
I have a diagnosis of smoldering multiple myeloma at an intermediate or high risk.
See 1 more

Exclusion Criteria

I have been diagnosed with plasma cell leukemia.
Pregnant or lactating females
I have not had systemic treatment for SMM, including the prohibited ones.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients receive personalized vaccine subcutaneously on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles.

24 weeks
12 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months
4 visits (in-person)

Treatment Details

Interventions

  • Vaccine Therapy
Trial Overview The study is testing a personalized vaccine made from the patient's own blood and bone marrow to see if it can stimulate the immune system to destroy cancer cells in patients with smoldering multiple myeloma. It also involves radiography of biopsy specimens and Lenalidomide therapy.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Stage II (personalized vaccine, lenalidomide)Experimental Treatment3 Interventions
Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Patients also receive lenalidomide PO on days 1-21. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.
Group II: Stage I (personalized vaccine)Experimental Treatment2 Interventions
Patients undergo collection of blood and bone marrow for making the vaccine. Patients then receive personalized vaccine SC on days 1 and 15 of cycles 1-2 and on day 1 of cycles 3-6. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

Find a Clinic Near You

Who Is Running the Clinical Trial?

M.D. Anderson Cancer Center

Lead Sponsor

Trials
3,107
Recruited
1,813,000+

Findings from Research

In a study of 44 patients with multiple myeloma, the two-dose SARS-CoV-2 mRNA vaccination showed low rates of adverse reactions, similar to those seen in general vaccine trials.
A high percentage of patients (93% on therapy and 94% not on therapy) developed detectable antibodies after the second dose, indicating strong immunogenicity and providing reassurance for vaccine-hesitant patients with multiple myeloma.
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.Greenberg, RS., Ruddy, JA., Boyarsky, BJ., et al.[2023]
Chimeric antigen receptor T cells targeting the BCMA protein show promise as a potent treatment for multiple myeloma, based on preliminary results from an ongoing phase I clinical trial in China.
The therapy was well tolerated by patients and led to complete and durable responses in those with relapsed or refractory multiple myeloma.
Sending CAR T Cells After Multiple Myeloma.[2018]

References

Vaccination of multiple myeloma: Current strategies and future prospects. [2016]
An Allogeneic Multiple Myeloma GM-CSF-Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission. [2022]
Dendritic cell-based immunotherapy in multiple myeloma. [2019]
4.Czech Republicpubmed.ncbi.nlm.nih.gov
[The preparation of anticancer vaccine for patients with multiple myeloma on the base of monoclonal immunoglobulin loaded dendritic cells]. [2010]
Cellular and vaccine immunotherapy for multiple myeloma. [2023]
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma. [2023]
Vaccination in Multiple Myeloma: Review of Current Literature. [2022]
Sending CAR T Cells After Multiple Myeloma. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security